DOUBLE BLIND STUDY WITH ORAL ILOPROST AND PLACEBO IN RAYNAUD'S PHENOMENON

继发于系统性硬化症（硬皮病）的雷诺现象是一种 使人虚弱的状况伊洛前列素（伊洛前列素-β-环糊精包合物） 是一种前列环素（PGI 2）类似物，显示可有效降低 硬皮病雷诺现象的频率和严重程度， 静脉注射 这是一项多中心研究，以评估有效性 口服伊洛前列素50的安全性 mcg b.i.d.对于整个治疗期 6周。 患者完成的维舒利类似物量表 评分是主要的结果变量。

Raynaud's phenomenon secondary to systemic sclerosis (scleroderma) is a debilitating condition. Iloprost (iloprost-beta-cyclodextrim-clathrate) is a prostacyclin (PGI2) analog shown to be effective in reducing the frequency & severity of Raynaud's phenomenon in scleroderma when given intravenously. This is a multicenter study to evaluate the effectiveness and safety of oral Iloprost 50 mcg b.i.d. for a total treatment period of 6 weeks. The patient-completed visulanalog scale Raynaud's condition score is the primary outcome variable.